American Trypanosomiasis (Chagas Disease)

Area of Science:

• Infectious Diseases
• Cardiology
• Parasitology

Background:

• American trypanosomiasis, or Chagas disease, is caused by the parasite Trypanosoma cruzi.
• Global migration has led to the worldwide spread of Chagas disease.
• While acute infections may resolve spontaneously, a substantial portion of individuals develop chronic complications.

Purpose of the Study:

• To review the current understanding of Chagas disease epidemiology and clinical progression.
• To discuss the controversies and ongoing investigations regarding etiologic treatment in asymptomatic carriers and early cardiomyopathy patients.
• To highlight the rapid progression of heart failure and its impact on morbidity and mortality.

Main Methods:

• Literature review of Chagas disease epidemiology, clinical manifestations, and treatment strategies.
• Analysis of data on the progression of cardiomyopathy and heart failure in chronic Chagas disease.
• Evaluation of current guidelines and research on etiologic treatment efficacy.

Main Results:

• Chagas disease, endemic to the Americas, is now a global health concern due to migration.
• A significant percentage (20-40%) of infected individuals develop cardiomyopathy 20-30 years post-infection.
• Heart failure progression in Chagas disease is rapid, leading to high morbidity and mortality.

Conclusions:

• Etiologic treatment is recommended for acute, congenital, and reactivation cases, and in women of childbearing age.
• Treatment efficacy in asymptomatic carriers and those with early cardiomyopathy requires further investigation.
• Effective management strategies are crucial to mitigate the rapid progression of heart failure and reduce mortality in Chagas disease.